IDH Mutation Status is Associated with Distinct Vascular Gene Expression Signatures in Lower-grade Gliomas

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2018 May 31

PMID 29846705

Citations 40

Authors

Lei Zhang

Liqun He

Roberta Lugano

Kenney Roodakker

Michael Bergqvist

Anja Smits

Anna Dimberg

Affiliations

Soon will be listed here.

Abstract

Background: Vascular gene expression patterns in lower-grade gliomas (LGGs; diffuse World Health Organization [WHO] grades II-III gliomas) have not been thoroughly investigated. The aim of this study was to molecularly characterize LGG vessels and determine if tumor isocitrate dehydrogenase (IDH) mutation status affects vascular phenotype.

Methods: Gene expression was analyzed using an in-house dataset derived from microdissected vessels and total tumor samples from human glioma in combination with expression data from 289 LGG samples available in the database of The Cancer Genome Atlas. Vascular protein expression was examined by immunohistochemistry in human brain tumor tissue microarrays (TMAs) representing WHO grades II-IV gliomas and nonmalignant brain samples. Regulation of gene expression was examined in primary endothelial cells in vitro.

Results: Gene expression analysis of WHO grade II glioma indicated an intermediate stage of vascular abnormality, less severe than that of glioblastoma vessels but distinct from normal vessels. Enhanced expression of laminin subunit alpha 4 (LAMA4) and angiopoietin 2 (ANGPT2) in WHO grade II glioma was confirmed by staining of human TMAs. IDH wild-type LGGs displayed a specific angiogenic gene expression signature, including upregulation of ANGPT2 and serpin family H (SERPINH1), connected to enhanced endothelial cell migration and matrix remodeling. Transcription factor analysis indicated increased transforming growth factor beta (TGFβ) and hypoxia signaling in IDH wild-type LGGs. A subset of genes specifically induced in IDH wild-type LGG vessels was upregulated by stimulation of endothelial cells with TGFβ2, vascular endothelial growth factor, or cobalt chloride in vitro.

Conclusion: IDH wild-type LGG vessels are molecularly distinct from the vasculature of IDH-mutated LGGs. TGFβ and hypoxia-related signaling pathways may be potential targets for anti-angiogenic therapy of IDH wild-type LGG.

Citing Articles

Mechanism analysis and targeted therapy of IDH gene mutation in glioma.

Ma X, Sun C, Ding X, Xu J, Zhang Y, Deng T Am J Cancer Res. 2025; 15(1):248-270.

PMID: 39949933 PMC: 11815359. DOI: 10.62347/NSXC2205.

The Three Pillars of Glioblastoma: A Systematic Review and Novel Analysis of Multi-Omics and Clinical Data.

De Luca C, Virtuoso A, Papa M, Cirillo G, La Rocca G, Corvino S Cells. 2024; 13(21.

PMID: 39513861 PMC: 11544881. DOI: 10.3390/cells13211754.

Diffuse glioma molecular profiling with arterial spin labeling and dynamic susceptibility contrast perfusion MRI: A comparative study.

Prysiazhniuk Y, Server A, Leske H, Bech-Aase O, Helseth E, Eijgelaar R Neurooncol Adv. 2024; 6(1):vdae113.

PMID: 39036439 PMC: 11259011. DOI: 10.1093/noajnl/vdae113.

Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in....

Trieu V, Maida A, Qazi S Cancers (Basel). 2024; 16(6).

PMID: 38539537 PMC: 10968971. DOI: 10.3390/cancers16061202.

CD93 maintains endothelial barrier function and limits metastatic dissemination.

Vemuri K, de Alves Pereira B, Fuenzalida P, Subashi Y, Barbera S, van Hooren L JCI Insight. 2024; 9(7).

PMID: 38441970 PMC: 11128212. DOI: 10.1172/jci.insight.169830.

References

Park J, Kim I, Han S, Park I, Kim C, Bae J . Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment. Cancer Cell. 2017; 31(1):157-158. DOI: 10.1016/j.ccell.2016.12.009. View

Madden S, Cook B, Nacht M, Weber W, Callahan M, Jiang Y . Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol. 2004; 165(2):601-8. PMC: 1618572. DOI: 10.1016/s0002-9440(10)63324-x. View

Vanlandewijck M, He L, Mae M, Andrae J, Ando K, Del Gaudio F . A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018; 554(7693):475-480. DOI: 10.1038/nature25739. View

Kelly P . Gliomas: Survival, origin and early detection. Surg Neurol Int. 2011; 1:96. PMC: 3019361. DOI: 10.4103/2152-7806.74243. View

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

Takano S . Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation. Brain Tumor Pathol. 2012; 29(2):73-86. DOI: 10.1007/s10014-011-0077-6. View

Gururangan S, Fangusaro J, Poussaint T, McLendon R, Onar-Thomas A, Wu S . Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2013; 16(2):310-7. PMC: 3895377. DOI: 10.1093/neuonc/not154. View

Dimberg A . The glioblastoma vasculature as a target for cancer therapy. Biochem Soc Trans. 2014; 42(6):1647-52. DOI: 10.1042/BST20140278. View

Langenkamp E, Zhang L, Lugano R, Huang H, Elhassan T, Georganaki M . Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival. Cancer Res. 2015; 75(21):4504-16. DOI: 10.1158/0008-5472.CAN-14-3636. View

10.

Wragg J, Finnity J, Anderson J, Ferguson H, Porfiri E, Bhatt R . MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome. Cancer Res. 2016; 76(8):2314-26. PMC: 4875769. DOI: 10.1158/0008-5472.CAN-15-1364. View

11.

Pen A, Moreno M, Martin J, Stanimirovic D . Molecular markers of extracellular matrix remodeling in glioblastoma vessels: microarray study of laser-captured glioblastoma vessels. Glia. 2007; 55(6):559-72. DOI: 10.1002/glia.20481. View

12.

Scholz A, Harter P, Cremer S, Yalcin B, Gurnik S, Yamaji M . Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol Med. 2015; 8(1):39-57. PMC: 4718155. DOI: 10.15252/emmm.201505505. View

13.

Essaghir A, Toffalini F, Knoops L, Kallin A, van Helden J, Demoulin J . Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data. Nucleic Acids Res. 2010; 38(11):e120. PMC: 2887972. DOI: 10.1093/nar/gkq149. View

14.

Gravendeel L, Kouwenhoven M, Gevaert O, de Rooi J, Stubbs A, Duijm J . Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009; 69(23):9065-72. DOI: 10.1158/0008-5472.CAN-09-2307. View

15.

Zhang L, Dimberg A . Pleiotrophin is a driver of vascular abnormalization in glioblastoma. Mol Cell Oncol. 2017; 3(6):e1141087. PMC: 5160416. DOI: 10.1080/23723556.2016.1141087. View

16.

Tu T, Zhang C, Yan H, Luo Y, Kong R, Wen P . CD146 acts as a novel receptor for netrin-1 in promoting angiogenesis and vascular development. Cell Res. 2015; 25(3):275-87. PMC: 4349246. DOI: 10.1038/cr.2015.15. View

17.

van den Bent M . Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. Neuro Oncol. 2014; 16(12):1570-4. PMC: 4232091. DOI: 10.1093/neuonc/nou297. View

18.

Kickingereder P, Sahm F, Radbruch A, Wick W, Heiland S, von Deimling A . IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep. 2015; 5:16238. PMC: 4633672. DOI: 10.1038/srep16238. View

19.

Weller M, van den Bent M, Tonn J, Stupp R, Preusser M, Cohen-Jonathan-Moyal E . European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017; 18(6):e315-e329. DOI: 10.1016/S1470-2045(17)30194-8. View

20.

Ishihara H, Kubota H, Lindberg R, Leppert D, Gloor S, Errede M . Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor beta2 involves matrix metalloproteinases and tight junction proteins. J Neuropathol Exp Neurol. 2008; 67(5):435-48. DOI: 10.1097/NEN.0b013e31816fd622. View